Zosano pharma corp (ZSAN)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14
Revenue

0

0

-

-

-

-

License fees

-

-

-

-

170

1,955

Collaboration revenue

-

-

-

-

143

906

Revenue

-

-

0

0

313

-

Total revenue

-

-

-

-

-

2,861

Operating expenses
Cost of license fees revenue

-

-

-

-

-

100

Research and development

25,385

25,508

20,118

20,457

20,366

10,953

General and administrative

11,812

9,357

8,182

8,176

6,315

4,420

Asset Impairment Charges

0

511

70

-

-

-

Total operating expenses

37,197

35,376

28,370

28,633

26,681

15,473

Loss from operations

-37,197

-35,376

-28,370

-28,633

-26,368

-12,612

Other income (expense)
Interest income

207

381

75

-

-

-

Interest Expense

523

379

817

-

-

-

Interest income (expense), net

-

-

-

-1,192

-1,564

-1,848

Interest income

-

-

-

-

-

0

Other income, net

-76

16

7

-7

-97

-93

Loss before provision for income taxes

-37,589

-35,358

-29,105

-29,832

-

-

Provision for income taxes

0

0

0

0

-

-

Warrant revaluation income

-

-

-

-

-48

185

Gain on debt forgiveness

-

-

-

-

-

497

Loss on debt extinguishment

-

-

-

-

-446

0

Net Income (Loss) Attributable to Parent

-37,589

-35,358

-29,105

-29,832

-28,427

-14,241

Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent

5

-5

0

-

-

-

Unrealized gain (loss) on marketable securities, net of tax effect

-

-

-

-

-46

0

Comprehensive loss

-37,584

-35,363

-29,105

-

-28,473

-14,241

Net loss per common share – basic and diluted (in USD per share)

-2.29

-3.74

-16.82

-43.36

-2.49

-2.78

Weighted-average shares used in computing net loss per common share – basic and diluted (in shares)

16,383

9,452

1,730

688

11,414

5,128